Alnylam Assist: Screening for Familial Amyloidotic Polyneuropathy (FAP) in TTR Amyloidosis

Size: px

Start display at page:

Download "Alnylam Assist: Screening for Familial Amyloidotic Polyneuropathy (FAP) in TTR Amyloidosis"

Myrtle Gallagher
5 years ago
Views:

1 FREE Screening Program* Alnylam Assist: Screening for Familial Amyloidotic Polyneuropathy (FAP) in TTR Amyloidosis Alnylam Pharmaceuticals, Inc. is committed to advancing the diagnosis and treatment of FAP. As part of our commitment, Alnylam is now sponsoring free third party screening for patients who may carry a genetic mutation known to be associated with FAP. *Available only in the US.

2 Why screen your patients for Familial Amyloidotic Polyneuropathy (FAP) FAP is an inherited genetic disorder caused by deposition of liver-derived TTR amyloid in various tissues and organs. This progressive condition remains significantly underdiagnosed and has limited treatment options. FREE Screening Program* Diagnosing FAP can be a challenge. Patients often exhibit symptoms commonly associated with idiopathic polyneuropathies. To promote accurate diagnosis and appropriate treatment, Alnylam Assist offers free third party screening for family members of patients diagnosed with FAP as well as for patients experiencing clinical signs and symptoms of this condition. FAP symptoms experienced at disease onset Sensory symptoms Motor symptom Autonomic symptoms Loss of touch/pain 82% Tingling/ pins and needles 80% Weakness 67% Constipation/diarrhea 55% Sexual dysfunction 53% Consider screening for any patient with a family history of FAP. Source: Suanprasert N, et al. J Neurol Sci *Available only in the US.

3 Alnylam Assist: Simple, Complimentary Screening Complete the included LabCorp account setup form Form for FAP testing is enclosed Complete LabCorp requisition form To be sent by LabCorp after account setup is completed. To ensure your practice or patient will not be billed, please use the requisition form sent by LabCorp only for the FAP Screening Program. Submit the requisition form to LabCorp Phone: Fax: Attention: Jill Hulford Take a 4 ml whole blood sample Use a standard 4.0 ml lavender-top (EDTA) tube Send the sample to LabCorp Shipping and specimen handling instructions are provided by LabCorp after account setup Receive your patient s results in 2-3 weeks Results will be faxed to your clinic For assistance with the LabCorp account setup form, contact LabCorp by calling For more information about FAP, contact Alnylam by calling Alnylam will not receive any personally identifiable patient information through this screening program. s Screening information sheet to distribute to patients you believe may benefit from this free FAP screening program. s Account setup form to complete and send to LabCorp.

4 Tremendous advances are being made in Familial Amyloidotic Polyneuropathy (FAP) research. This free screening program offered by Alnylam gives patients and their physicians access to laboratory testing for genetic mutations known to be associated with this serious, life-threatening disease. This screening is expected to help enable earlier diagnosis and enhance a patient s knowledge of the disorder and how it might affect them and their family members. It will also allow them to initiate discussions with their healthcare provider about their care, and potentially enable them to consider participating in ongoing clinical trials. Natacha T. Pires, MBBS, Director of Medical and Public Affairs, The Neuropathy Association Alnylam is a biopharmaceutical company developing a new class of innovative medicines. We have a core focus on therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. Learn more about Alnylam s clinical trial of a potential new treatment for FAP. Visit or call for more information Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA USA Rev_1_

5 Alnylam Assist: Free Screening for Familial Amyloidotic Polyneuropathy (FAP) * Your doctor believes you should be screened for familial amyloidotic polyneuropathy (FAP), an inherited genetic disease. Alnylam offers you this screening through an independent laboratory free of charge. Early diagnosis can assist patients with FAP in getting the help and support they need. How To Get Screened 1. Provide a blood sample Screening for FAP takes a small amount of blood. 2. Get your results from your doctor FAP screening results usually arrive in 2-3 weeks. If your results are positive When your results arrive, your doctor will tell you if you have a genetic mutation known to be associated with FAP. If you do, you are encouraged to discuss health care options with your doctor. If you need treatment, options may include drug therapy or a clinical trial. To learn more about clinical trials for FAP, visit or * Available only in the US. Alnylam will not receive any personally identifiable patient information through this screening program.

6 sponsored by

Education Brochure. Hereditary ATTR amyloidosis A closer look at an inherited condition

Education Brochure. Hereditary ATTR amyloidosis A closer look at an inherited condition Education Brochure Hereditary ATTR amyloidosis A closer look at an inherited condition What is hereditary ATTR (hattr) amyloidosis? hattr amyloidosis is caused by a gene change (mutation) that affects